TAK-831 + TAK-831 Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Nov 8, 2017 → Dec 27, 2018
NCT ID
NCT03214588About TAK-831 + TAK-831 Placebo
TAK-831 + TAK-831 Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT03214588. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03214588 | Phase 2 | Completed |
Competing Products
20 competing products in Friedreich Ataxia